• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    12/26/22 8:07:31 AM ET
    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email

    Gainers

    • Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $13.0 million.
    • DBV Technologies (NASDAQ:DBVT) shares moved upwards by 27.11% to $1.5. The company's market cap stands at $281.9 million.
    • Humanigen (NASDAQ:HGEN) shares rose 18.09% to $0.12. The company's market cap stands at $14.1 million.
    • Owlet (NYSE:OWLT) stock moved upwards by 13.28% to $0.82. The market value of their outstanding shares is at $93.8 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 13.06% to $0.24. The company's market cap stands at $7.9 million. The company's, Q4 earnings came out 3 days ago.
    • Personalis (NASDAQ:PSNL) shares moved upwards by 12.9% to $2.1. The company's market cap stands at $96.5 million.

    Losers

    • Applied Molecular (NASDAQ:AMTI) stock decreased by 27.2% to $0.75 during Monday's pre-market session. The market value of their outstanding shares is at $29.2 million.
    • Otonomy (NASDAQ:OTIC) stock declined by 22.08% to $0.06. The market value of their outstanding shares is at $3.4 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares declined by 18.61% to $1.05. The market value of their outstanding shares is at $6.8 million.
    • Athenex (NASDAQ:ATNX) stock fell 11.01% to $0.15. The market value of their outstanding shares is at $23.6 million.
    • Satsuma Pharmaceuticals (NASDAQ:STSA) stock declined by 9.38% to $0.76. The market value of their outstanding shares is at $25.3 million.
    • Aytu BioPharma (NASDAQ:AYTU) stock fell 8.73% to $0.19. The company's market cap stands at $11.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTI
    $ATNX
    $AYTU
    $DBVT

    CompanyDatePrice TargetRatingAnalyst
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Personalis Inc.
    $PSNL
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    Aytu BioPharma Inc.
    $AYTU
    6/30/2025$12.00Buy
    Ascendiant Capital Markets
    DBV Technologies S.A.
    $DBVT
    5/29/2025$7.25Sell
    Goldman
    Personalis Inc.
    $PSNL
    5/15/2025$6.00Buy
    Guggenheim
    More analyst ratings

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for commercial expansion Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial

    2/26/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Immuron Reports HY26 Results and Strategic Reset

    Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o

    2/25/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Owlet® Selects Hannah Cranston Media as Public Relations Agency of Record

    Award-Winning Agency to Lead Strategic Communication as Owlet Expands Its Mission to Bring More Wellness Insights and Better Starts to Families Worldwide Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today announced it has selected Hannah Cranston Media (HCM) as its public relations agency of record (AOR). Following a competitive review, Owlet selected HCM for its expertise in health tech, wellness, and consumer innovation, and its demonstrated ability to position mission-driven brands at the center of cultural and industry conversations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom

    2/24/26 8:45:00 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO AND COO Tachibana Aaron

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:51:27 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 4 filed by CHIEF MEDICAL OFFICER AND EVP Chen Richard

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:50:15 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 4 filed by SVP and Chief Legal Officer Moore Stephen Michael

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:48:57 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    SEC Filings

    View All

    SEC Form S-8 filed by Personalis Inc.

    S-8 - Personalis, Inc. (0001527753) (Filer)

    2/26/26 5:11:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Personalis Inc.

    10-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:11:12 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:05:35 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Disbrow Jarrett bought $24,999 worth of shares (16,666 units at $1.50), increasing direct ownership by 130% to 29,462 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:06:06 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Disbrow Joshua R. bought $99,999 worth of shares (66,666 units at $1.50), increasing direct ownership by 77% to 153,257 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:04:30 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    3/3/25 1:35:04 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Financials

    Live finance-specific insights

    View All

    Owlet to Report Fourth Quarter and Full Year 2025 Financial Results on March 5, 2026

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, plans to announce fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a business update. Participants may access the call at 833-470-1428 (domestic) or 646-844-6383 (international) and reference Access Code 211338. A simultaneous webcast may be accessed online at the Events section of Owlet's Investor Relations website at investors.owletcare.com.

    2/19/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

    SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

    11/14/24 3:34:00 PM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

    SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

    11/13/24 5:36:50 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $ATNX
    $AYTU
    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Resignation of Board Member

    Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the "Board"), effective immediately. "On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company," said Michel de Rosen, Chairman of the Board. "Since joining the Board in 2015, Daniel's experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors." "It has been a

    9/18/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care